BeStock  
Stocks › Biotechnology › IMVT

Immunovant IMVT

US equityMarket cap rank #1778Biotechnology
$31.77 −$0.75 (-2.31%)
Market closed · Nov 22, 5:10 am ET · Last extended-hours $31.51 -0.82%
Open$32.26
Prev close$32.52
Day range$31.61 – $32.77
Volume704.9K
Market cap$6.57B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q2, ended Sep 2026

Revenue$0.00
Operating profit-$104.16M+21.0% YoY
Net profit-$97.25M+23.1% YoY
Diluted EPS-$0.47+35.6% YoY
Free cash flow-$83.22M+18.8% YoY
Operating cash flow-$83.22M

Revenue, last 8 quarters

$0.0Dec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$0.0Jun '26$0.0Sep '26

Net profit, last 8 quarters

$-111.1MDec '24$-106.4MMar '25$-120.6MJun '25$-126.5MSep '25$-110.6MDec '25$-147.9MMar '26$-153.2MJun '26$-97.2MSep '26

Diluted EPS by quarter

-0.76Dec '24-0.64Mar '25-0.71Jun '25-0.73Sep '25-0.61Dec '25-0.73Mar '26-0.75Jun '26-0.47Sep '26

Free cash flow by quarter

$-100.6MDec '24$-110.8MMar '25$-117.4MJun '25$-102.5MSep '25$-92.3MDec '25$-95.1MMar '26$-124.4MJun '26$-83.2MSep '26

Annual revenue

$0.0FY21$0.0FY22$0.0FY23$0.0FY24$0.0FY25$0.0FY26

Profitability & balance sheet

Return on equity-86.5%
Return on assets-75.7%
Return on invested capital-91.2%
Current ratio7.31
Liabilities / assets13.7%
Cash & investments$722.27M
Net cash (debt)$722.27M

Income statement

Line item 2027 Q2 2027 Q1 2026 ANNUAL 2026 Q4 2026 Q3
Total Operating Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Operating Expense $104.16M $160.32M $532.90M $159.55M $114.36M
Selling and Admin Expenses $19.14M $17.69M $76.24M $17.27M $15.44M
-General & Admin Expense $19.14M $17.69M $76.24M $17.27M $15.44M
Research & Development $85.01M $142.63M $456.66M $142.29M $98.92M
Operating Profit -$104.16M -$160.32M -$532.90M -$159.55M -$114.36M
Net Non-Operating Interest Income (Expense) $6.90M $7.10M $25.33M $8.06M $5.33M
Non-Operating Interest Income $6.90M $7.10M $25.33M $8.06M $5.33M
Other Income (Expense) $12,000.00 $4,000.00 $2.18M $798,000.00 -$54,000.00
Other Non-Operating Income (Expenses) $12,000.00 $4,000.00 $2.18M $798,000.00 -$54,000.00
Pretax Profit -$97.25M -$153.22M -$505.39M -$150.70M -$109.08M
Tax $0.00 $0.00 $215,000.00 -$2.84M $1.55M
Net Profit -$97.25M -$153.22M -$505.61M -$147.86M -$110.64M
Profit from Continuing Operations -$97.25M -$153.22M -$505.61M -$147.86M -$110.64M
Net Income to Parent Company -$97.25M -$153.22M -$505.61M -$147.86M -$110.64M
Net Income to Common Stockholders -$97.25M -$153.22M -$505.61M -$147.86M -$110.64M
Basic EPS -$0.47 -$0.75 -$2.77 -$0.73 -$0.61
Diluted EPS -$0.47 -$0.75 -$2.77 -$0.73 -$0.61
Special Income (Charges) – – $0.00 – –
-Less:Restructuring and Mergern & Acquisition – – $0.00 – –

Balance sheet

Line item 2027 Q2 2027 Q1 2026 ANNUAL 2026 Q4 2026 Q3
Total Assets $760.97M $852.49M $957.01M $957.01M $1.05B
Total Current Assets $760.05M $851.18M $948.82M $948.82M $1.04B
Cash and Cash Equivalents & Short-Term Investments $722.27M $797.80M $902.11M $902.11M $994.53M
-Cash and Cash Equivalents $722.27M $797.80M $902.11M $902.11M $994.53M
Receivables $138,000.00 $697,000.00 $3.95M $3.95M $1.64M
-Accounts Receivable $138,000.00 $697,000.00 $1.13M $1.13M $1.64M
Other Current Assets $37.63M $52.68M $42.76M $42.76M $46.77M
Total Non-Current Assets $921,000.00 $1.31M $8.20M $8.20M $9.45M
Net PPE $262,000.00 $351,000.00 $515,000.00 $515,000.00 $531,000.00
Other Non-Current Assets $659,000.00 $961,000.00 $7.68M $7.68M $8.92M
Total Liabilities $104.02M $117.10M $104.42M $104.42M $66.26M
Total Current Liabilities $104.02M $117.10M $104.42M $104.42M $66.26M
Payables $6.79M $10.14M $7.72M $7.72M $8.62M
-Accounts Payable $6.79M $10.14M $7.54M $7.54M $8.62M
Current Accrued Expenses $89.89M $101.71M $79.87M $79.87M $42.34M
Total Non-Current Liabilities $0.00 $0.00 $0.00 $0.00 $0.00
Total Equity $656.95M $735.39M $852.59M $852.59M $986.14M
Stockholders' Equity $656.95M $735.39M $852.59M $852.59M $986.14M
Capital Stock $20,000.00 $20,000.00 $20,000.00 $20,000.00 $20,000.00
-Common Stock $20,000.00 $20,000.00 $20,000.00 $20,000.00 $20,000.00
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $2.65B $2.63B $2.60B $2.60B $2.58B
Retained Earnings -$2.00B -$1.90B -$1.75B -$1.75B -$1.60B
Gains/Losses Not Affecting Retained Earnings $519,000.00 $725,000.00 $730,000.00 $730,000.00 $1.20M
-Taxes Receivable – – $2.81M $2.81M –
-Gross PPE – – $515,000.00 $515,000.00 –
-Due to Related Parties Current – – $175,000.00 $175,000.00 $0.00
Short-Term Debt and Capital Lease Obligation – – $72,000.00 $72,000.00 –
-Current Capital Lease Obligation – – $72,000.00 $72,000.00 –

Cash flow

Line item 2027 Q2 2027 Q1 2026 ANNUAL 2026 Q4 2026 Q3
Operating Cash Flow -$83.22M -$124.41M -$407.31M -$95.06M -$92.33M
Net cash flow from continuing operations -$83.22M -$124.41M -$407.31M -$95.06M -$92.33M
Net Income from Continuing Operations -$97.25M -$153.22M -$505.61M -$147.86M -$110.64M
Depreciation & Depletion & Amortization $89,000.00 $92,000.00 $409,000.00 $96,000.00 $101,000.00
Other Non-Cash Items $27,000.00 $27,000.00 $99,000.00 $26,000.00 $25,000.00
Change in Working Capital $634,000.00 $14.93M $42.06M $41.53M $5.47M
-Change in Receivables $558,000.00 $436,000.00 -$1.40M -$1.82M $319,000.00
-Change in Prepaid Assets $12.89M -$4.95M $8.84M $4.31M $2.87M
-Change in Payables and Accrued Expense -$13.09M $12.68M $34.65M $37.84M $2.32M
-Change in Other Current Assets $276,000.00 $6.76M $69,000.00 $1.30M -$38,000.00
Financing Cash Flow $7.88M $20.10M $595.76M $3.64M $564.60M
Net Cash Flow from Continuing Financing Activities $7.88M $20.10M $595.76M $3.64M $564.60M
Proceeds from Stock Option Exercised $7.88M $20.10M $52.07M $3.56M $21.00M
Ending Cash Balance $722.27M $797.80M $902.11M $902.11M $994.53M
Net Change in Cash -$75.33M -$104.31M $188.44M -$91.43M $472.28M
Beginning Cash Balance $797.80M $902.11M $713.97M $994.53M $521.87M
Effect of Exchange Rate Changes -$191,000.00 -$4,000.00 -$299,000.00 -$988,000.00 $377,000.00
Free Cash Flow -$83.22M -$124.41M -$407.32M -$95.07M -$92.33M
-Change in Other Current Liabilities – – -$99,000.00 – –
Net cash flow from investing – – -$8,000.00 -$8,000.00 $0.00
Net Cash Flow from Continuing Investing Activities – – -$8,000.00 -$8,000.00 $0.00
Net PPE Purchase and Sale – – -$8,000.00 -$8,000.00 $0.00
Net Common Stock Issuance – – $544.19M $0.00 –
Net Other Financing Charges – – -$504,000.00 $82,000.00 –

Discussion

No comments yet — be the first to weigh in on IMVT.

Sign in to join the discussion.

Scroll to Top